Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer

He-Yang Zhang1,2,3†, Hai-Lun Xie1,2,3†, Guo-Tian Ruan1,2,3†, Qi Zhang1,2,3, Yi-Zhong Ge1,2,3, Xiao-Yue Liu1,2,3, Meng Tang1,2,3, Meng-Meng Song1,2,3, Shi-Qi Lin1,2,3, Ming Yang1,2,3, Xiao-Wei Zhang1,2,3, Hong-Xia Xu1,2,3, Chun-Hua Song1,2,3 and Han-Ping Shi1,2,3*

Abstract

Background: Systemic inflammation is currently regarded as a hallmark of cancer. This study aimed to accurately clarify the prognostic value of various inflammatory markers in patients with stage IV cancer.

Methods: This study assessed 2,424 patients with cancer diagnosed with cancer in tumor, node, metastasis (TNM) stage IV. After evaluating the predictive value of 13 inflammatory indicators for patient prognosis using the C index, the lymphocyte C-reactive protein ratio (LCR) was selected to elucidate the prognostic and predictive values in patients with stage IV cancer. Kaplan–Meier and Cox proportional hazards regression models were used to analyze long-term survival.

Results: A total of 1,457 men (60.1%) and 967 women (39.9%) diagnosed with TNM stage IV cancer were enrolled. A ratio of 2,814 was defined as the optimal cut-off value for the LCR. The LCR was the most accurate prognosis predictor for patients with stage IV cancer among the 13 inflammatory nutritional markers evaluated. The multivariate-adjusted restricted cubic spline plot suggested that LCR had an L-shaped dose–response association with all-cause mortality risk. Patients with lower LCR levels tended to present with worse prognoses. Kaplan–Meier curves and log-rank test results showed that the high LCR groups (LCR ≥ 2,814) exhibited a better prognosis, whereas patients with stage IV cancer of different sex and tumor types (for example, gastrointestinal tumor, non-gastrointestinal tumor, and lung cancer) had a worse survival time.

Conclusion: The LCR score can be regarded as a stable and useful biomarker to predict prognosis in patients with TNM stage IV compared to other evaluated inflammation indicators.

Keywords: Systemic inflammation, Lymphocyte-C-reactive protein ratio, Cancer, Prognosis, Patients with stage IV cancer

Background

According to GLOBOCAN 2020 estimates, there were 19,292,789 new cancer cases worldwide, and 9,958,133 patients with cancer died in 2020. Lung cancer remains the leading cause of cancer-related deaths, with an estimated 1,796,144 deaths, accounting for 18.0 percent of total cancer deaths, followed by colorectal cancer (9.4%), liver cancer (8.3%), gastric cancer (7.7%), and breast...
cancer (6.9%) [1]. Cancer is the second leading cause of
death in the world [1]. Therefore, there is an urgent need
to explore the pathogenesis, early prevention, and diag-
nosis of cancer.

Despite advances in tumor screening, detection meth-
ods, and surgical modalities, the ability to predict long-
term prognosis in patients with stage IV cancer after
tumor resection remains poor. A growing number of
studies have shown that systemic inflammatory response
is correlated with cancer survival and may serve as a
prognostic marker for human malignancies [2, 3]. As the
seventh hallmark of cancer, systemic inflammation has
been confirmed to be closely related to the development
and metastasis of many malignant tumors [4, 5]. There
are usually inflammatory factors present in the tumor
microenvironment, and inflammation provides possible
conditions for tumor occurrence [6]. However, it is
unclear which components of the systemic inflammatory
response can best predict survival rates in patients with
stage IV cancer.

To further evaluate inflammation and its prognosis, a
prognostic score based on inflammation was developed,
including the neutrophil-to-lymphocyte ratio (NLR)
[7], the platelet to lymphocyte ratio (PLR) [8], the Prog-
ostic Index (PI) [9], the Prognostic Nutritional Index
(PNI) [10], the Glasgow Prognostic Score (GPS) [2] and
the modified Glasgow prognostic score (mGPS) [11].
Recently, another measurement method of the systemic
inflammatory response, the lymphocyte to C-reactive
protein (CRP) ratio (LCR) has been proposed for patients
with rectal cancer, colorectal cancer, and gastric cancer
[12–14]. As a promising marker, LCR has demonstrated
higher ability in predicting cancer surgery and oncologi-
cal outcomes in gastric cancer, rectal cancer, and chol-
angiocarcinoma compared to NLR, CRP, nutritional
risk index (NRI), PLR, PI, PNI, GPS, and mGPS [12–17].
However, the prognostic potential of LCR in patients
with advanced cancer has not been explored. In this
study, we aimed to explore the prognostic value of LCR in
patients with stage IV cancer and compare its prognos-
tic predictive power with existing prognostic markers in
patients with stage IV cancer.

Methods

Study population and design

This multicenter observational study was based on the
Common Cancer in China (INSCOC) cohort (registra-
tion number: ChiCTR1800020329; http://www.chictr.
org.cn), a prospective cohort that collected data from
multiple centers in China; study design, The method-
ology and research development process have been
described previously [18]. The cohort included 2424
patients aged 18–95 years with pathologically diagnosed
solid malignancies, a total of 1457 men (60.1%) and 967
women (39.9%), with a mean age of 60.18 years. Patients
with multiple hospitalizations for cancer treatments (all
therapies, including surgery, chemotherapy, radiotherapy,
and others) were treated as one case; the baseline data
from the first assessment were analyzed. Patients with
serious active infections, continuous anti-inflammatory
use in the past 6 months, or acquired immunodeficiency
syndrome were excluded. In addition, we excluded
patients with cancer TNM stages I, II, and III. Figure 1
shows a flowchart of the study screening process. The
study was approved by the institutional review boards
of Shijitan Hospital, and written informed consent was
obtained from all the participants. All methods were
carried out in accordance with relevant guidelines and
regulations.

Patient characteristics

Patient age, sex, body mass index (BMI), primary tumor
type, TNM stage, smoking history, drinking history, and
family history were collected from electronic medical
records. The patients-generated subjective nutritional
assessment (PG-SGA) and Karnofsky Performance Sta-
tus Scale (KPS) were evaluated and recorded by trained
staff at baseline. Blood samples were collected within
24 h of admission after fasting overnight. The follow-
ing data were collected from blood analysis: hemoglobin
(Hb), serum albumin, PLT, and CRP levels, and other
serological indicators. To eliminate differences caused by
different laboratory equipment, all measurements were
standardized.

Outcomes and follow-up

All patients were followed-up regularly via telephone or
outpatient visits, and clinical result information was col-
lected. Telephone follow-up mainly included inquiries
about survival and treatment, and outpatient follow-up
mainly included physical examination, blood drawing,
imaging, and an endoscopic examination when necessary.
The primary endpoint of this study was overall survival
(OS), which was defined as the time interval between the
first clinical evaluation and death, withdrawal from the
study, final follow-up, or last contact. Secondary end-
points included length of stay (LOS), cost, and the KPS
score (a self-scoring of health status with a total score
of 100 points and 10 points per level). The 90-day out-
comes were defined as all deaths within 90 days of patient
enrollment in this study.

Statistical analyses

The demographic characteristics of the study popula-
tion were calculated, with continuous variables expressed
as either mean ± standard deviation or median and
interquartile range. Categorical variables are presented as numbers and percentages (n, %). Comparisons of differences between groups were conducted using the independent Student’s t-test or non-parametric tests for comparing continuous variables, and Chi-square test or Fisher’s exact test for comparing categorical variables. The Harrell C-index and area under the time-dependent curve (AUC) were calculated using continuous variables to evaluate and compare the predictive ability of inflammatory nutritional and anthropometric indicators for patient survival. Covariates and potential confounders were selected based on the results of previous studies. Restricted cubic spine (RCS) function with 3 knots was performed to evaluate the effects of continuous LCR on survival. Univariate and multivariate Cox regression analyses were used to evaluate the hazard ratios (HRs) and 95% confidence intervals (CIs) for important prognostic factors based on OS. A sensitivity analysis, excluding patients who died within 6 months of enrollment, was performed. Kaplan–Meier curves and log-rank tests were used to evaluate time-patient survival trends and compare survival between groups. Logistic regression models adjusted for different variables were used to assess the association of markers with patients’ daily functions and short-term outcomes. Differences were considered statistically significant for two-sided p-values < 0.05. Reported P values were not corrected for multiple testing. All statistical analyses were performed using the R software (version 4.1.1; The R Project for Statistical Computing, Vienna, Austria).

Results

Study participants and characteristics
We enrolled 2,424 (1,457 men, 60.1%; 967 women, 39.9%; mean age 60.18 years) patients with cancer diagnosed with TNM stage IV (Fig. 1). Optimal cut-off point values for all inflammatory nutritional indicators were obtained according to OS and using maximum selection rank statistics. The optimal critical value for LCR was determined as 2,814 (See Additional file 1).

Next, we assessed the relationship between clinico-pathological factors and LCR in patients with stage IV
cancer. Patients in the low LCR group (≤ 2,500) were more likely to be male (p < 0.001), older (p < 0.001), and to have a low BMI (p = 0.002) and various cancers such as lung cancer (p < 0.001), gastric cancer (p < 0.001), and liver cancer (p < 0.001) than those in the high LCR group (Table 1). In addition, these patients were more likely to have low PG-SGA scores, high KPS scores, high albumin Hb levels, and RBC levels, and low PLT levels (Table 1).

Furthermore, a Spearman rank correlation test was performed to compare the correlations between LCR and age, BMI, KPS, PG-SGA, and QLQ-C30 (Fig. 2). LCR was negatively correlated with age (men, r = -0.072; women, r = -0.047). The PG-SGA and QLQ-C30 exhibited a strong negative association with LCR (men: r = -0.26; women: r = -0.27; men: r = -0.21; women: r = -0.17), whereas BMI and KPS were positively associated with LCR (men: r = 0.11; women: r = 0.1; men: r = 0.19; women: r = 0.2) (Fig. 2). Furthermore, we found that LCR levels were significantly enhanced in male patients with stage IV cancer, aged < 65 years, BMI greater than 24, LOS less than 7, and hospitalization expenses less than or equal to 10,000 yuan, while there was no significant difference in LCR levels among patients with stage IV cancer with gastrointestinal tumors, non-gastrointestinal tumors, and lung cancer (Fig. 3).

Table 1: Baseline characteristics of the study population

| Characteristic                   | Overall | High LCR | Low LCR | p-value |
|---------------------------------|---------|----------|---------|---------|
| Sex, male, n (%)                | N = 2424| N = 1387 | N = 1037|         |
| Age, years, mean (SD)           | 60.18 (11.18) | 62.00 [54.00, 68.00] | 60.00 [52.00, 66.00] | < 0.001 |
| BMI, mean (SD)                  | 22.09 (3.13) | 21.90 [19.70, 24.10] | 22.30 [20.10, 24.60] | 0.002   |
| PG-SGA (median [IQR])           | 6.83 (5.12) | 7.00 [4.00, 11.00] | 4.00 [2.00, 8.00] | < 0.001 |
| KPS (median [IQR])              | 82.60 (13.84) | 80.00 [70.00, 90.00] | 90.00 [80.00, 90.00] | < 0.001 |
| TP (median [IQR])               | 68.40 (7.04) | 68.00 [63.05, 73.00] | 69.30 [65.00, 73.40] | < 0.001 |
| Scr (median [IQR])              | 4.63 (1.22) | 4.36 [3.73, 5.14] | 4.66 [4.01, 5.39] | < 0.001 |
| Alb (median [IQR])              | 38.17 (33.62) | 36.80 [33.35, 40.00] | 36.75 [35.90, 37.20] | < 0.001 |
| Tch (median [IQR])              | 23.63 (38.74) | 21.30 [9.57, 37.00] | 40.50 [37.70, 43.00] | < 0.001 |
| Glu (median [IQR])              | 5.86 (1.95) | 5.47 [4.86, 6.40] | 5.26 [4.80, 5.97] | < 0.001 |
| Hb (median [IQR])               | 119.85 (29.05) | 120.00 [102.00, 134.00] | 130.00 [115.00, 140.00] | < 0.001 |
| N (median [IQR])                | 4.82 (3.33) | 4.80 [3.40, 6.66] | 3.40 [2.57, 4.64] | < 0.001 |
| L (median [IQR])                | 1.49 (0.82) | 1.25 [0.90, 1.67] | 1.59 [1.24, 1.97] | < 0.001 |
| RBC (median [IQR])              | 6.06 (82.34) | 4.07 [3.58, 4.53] | 4.30 [3.91, 4.69] | < 0.001 |
| PLT (median [IQR])              | 237.93 (98.06) | 239.00 [175.50, 305.00] | 213.00 [168.00, 268.00] | < 0.001 |
| Lung cancer, yes, n (%)         | 971 (37.8) | 539 (38.9) | 378 (36.5) | < 0.001 |
| Gastric cancer, yes, n (%)      | 276 (11.4) | 155 (11.2) | 121 (11.7) | < 0.001 |
| Liver cancer, yes, n (%)        | 92 (3.8) | 63 (4.5) | 29 (2.8) | < 0.001 |
| Breast cancer, yes, n (%)       | 136 (5.6) | 53 (3.8) | 83 (6.0) | < 0.001 |
| Esophageal cancer, yes, n (%)   | 156 (5.95) | 91 (6.5) | 65 (6.2) | < 0.001 |
| Gynecological tumor, yes, n (%) | 67 (2.8) | 40 (2.9) | 27 (2.6) | < 0.001 |
| Urinary cancer, yes, n (%)      | 62 (2.5) | 40 (2.8) | 22 (2.1) | < 0.001 |
| Pancreatic cancer, yes, n (%)   | 97 (4.0) | 57 (4.1) | 40 (3.9) | < 0.001 |
| Nasopharyngeal cancer, yes, n (%) | 52 (2.1) | 24 (1.7) | 28 (2.7) | < 0.001 |
| Colorectal cancer, yes, n (%)   | 396 (16.3) | 206 (14.9) | 190 (18.3) | < 0.001 |
| Biliary Tract cancer, yes, n (%) | 36 (1.5) | 31 (2.2) | 5 (0.5) | < 0.001 |
| Other cancer, yes, n (%)        | 136 (5.6) | 87 (6.3) | 49 (4.7) | < 0.001 |
| Surgery, yes, n (%)             | 1492 (61.6) | 923 (66.5) | 569 (54.9) | < 0.001 |
| Radiotherapy, yes, n (%)        | 2114 (87.2) | 1203 (86.7) | 911 (87.8) | 0.452 |
| Chemotherapy, yes, n (%)        | 897 (37.0) | 534 (38.5) | 363 (35.0) | 0.085 |

BMI: Body mass index, PG-SGA: Patients-generated subjective nutritional assessment, KPS: Karnofsky performance status Scale, TP: Total protein, Scr: Serum creatinine, Alb: Albumin, Tch: Total cholesterol, CRP: C-reactive protein, Glu: Glucose, Hb: Hemoglobin, N: Neutrophils, L: Lymphocytes, RBC: Red blood cell, PLT: Platelets
Comparison of LCR scores and current commonly used inflammation-based prognostic systems

In order to judge the prognostic value of the index from different dimensions, we used the time-dependent AUC curve to observe the time dynamic prediction ability of the index, and we also used the C index for comprehensive survival prediction. We first identified the accuracy of 15 frequently used scoring indices of patients with stage IV cancer. The LCR scores consistently had higher C-index values than the other scoring systems (See Additional file 2). The statistical differences in AUC values between LCR and other scores were also compared and showed that the AUC values of LCR were higher than those of other indicators for patients with stage IV cancer (See Additional file 3). These results demonstrated that LCR was more accurate than other inflammation-related indicators in predicting the prognosis of patients with stage IV cancer.

Association of LCR with OS in patients with stage IV cancer

Next, we assayed the association between LCR and the HR for OS of stage IV cancer. When analyzed as a continuous variable, the multivariate-adjusted RCS with a cubic spline function suggested that LCR had an L-shaped dose–response association with the all-cause mortality risk in patients with stage IV cancer (Fig. 4), which indicated that the lower LCR levels tended to have a worse prognosis. Furthermore, we analyzed other prognostic indicators (See Additional file 4), where NLR, PLR, GLR, SII, CAR, controlling nutritional status score, and CRP were negatively associated with prognosis, and ALI, GNRI, mGNRI, AGR, PNI, and NRI were positively associated with prognosis. In the multivariate Cox regression models (Table 2), continuous LCR as linear predictor was positively correlated with better prognosis (HR 0.84 per standard deviation increase, 95% CI: 0.77–0.91). LCR was divided into quartiles, and compared with the first quartile, the second (1.83–2.95), third (2.95–4.8) and fourth
quartiles (> 4.80) were all positively correlated with a better prognosis (p < 0.001).

To further explore the potential impact of LCR on patients with stage IV cancer, we used stratified analyses to evaluate the relationship between LCR and HR of OS. As shown in Fig. 5, LCR showed a trend consistent with the main outcome in most subgroups, while there was no interaction between LCR and each subgroup factor. These results suggest that LCR can be used as an independent prognostic predictor in patients with stage IV cancer.

Fig. 3  LCR in patients with TNM stage IV. Notes: LCR, Lymphocyte to C-reactive protein ratio; TNM, tumor, node, metastasis; BMI, body mass index

Fig. 4  The association between LCR and hazard ratio of overall survival. Splines is adjusted by sex, age, BMI, tumor type, radiotherapy, chemotherapy, KPS score, albumin level, total bilirubin level, red blood cell count, platelet count, hand grip strength, reported reduced food intake, reported anorexia, and EORTC QLQ-C30 score. Abbreviations: LCR, lymphocyte C-reactive protein ratio; HR, hazard ratio; adj, adjusted; CI, confidence interval; BMI, body mass index; KPS, Karnofsky Performance Status Scale; QLQ-C30, EORTC Qly-C-30 questionnaire
We next used Kaplan–Meier curves and log-rank tests to evaluate time-patient survival trends and compare survival between groups. Patients with high LCR had significantly lower OS than those with low LCR (OS, 42.8% vs. 63.7%) (Fig. 6). We performed a subgroup survival analysis and found that patients with low LCR had worse survival than those with high LCR, in both men and women. Furthermore, in the subgroup analysis of different tumor types, we found that LCR could significantly stratify the prognosis of different tumor types, including gastrointestinal tumors, non-gastrointestinal tumors, and lung cancers (Fig. 6).

After 90 days of anti-cancer treatment, 199 patients died in the low LCR group, with a mortality rate of 14%, and 42 patients died in the high LCR group, with a mortality rate of 4%. Using logistic regression, we identified low LCR as an adverse factor affecting 90-day outcomes in patients with stage IV cancer (odds ratio [OR] = 1.003; 95% CI = 1.002 – 1.004, p < 0.001) (Table 3).

### Discussion

There is increasing evidence that inflammation/nutrition-based markers are reliable predictors of OS in patients with cancer; however, the best predictors for patients with stage IV cancer are unclear. In this study, we used a large cohort to evaluate and compare 15 kinds of inflammation/nutrition-based indicators and found that LCR was more accurate in predicting the prognosis of patients with stage IV cancer than other inflammation-related indicators. In addition, our findings indicated that a low LCR was also an adverse factor affecting the 90-day prognosis of patients with stage IV cancer.

As a systemic inflammatory mediator, CRP is an evolutionarily conserved innate immune polymer protein, which has been considered as an important biomarker to predict cancer patient survival [19, 20]. CRP is mainly produced in the liver in response to cytokines released by phagocytes under the conditions of trauma, infection, inflammation, and advanced cancer [21, 22]. In patients with advanced tumors, some inflammatory factors such as tumor necrosis factor alfa, interleukin 6, and interleukin 1 beta can induce the synthesis of CRP in hepatocytes while promoting angiogenesis to support tumor growth and anti-apoptosis capabilities to protect tumor cells. Therefore, high-level CRP is positively correlated with prognosis [23, 24]. Neutral granulocyte, lymphocyte, and platelet levels reflect the severity of inflammation, and an increasing amount of evidence shows that combinations of these systemic inflammatory parameters, such as the NLR and PLR, can provide prognostic information for some malignant tumors' prognosis [25]. LCR is directly related to lymphocyte counts and CRP levels. Our results showed that low-level LCRs were negatively correlated with patients with advanced tumor.

The advantage of LCR is that it can be measured quickly, inexpensively, and non-invasively; thus, it is widely used in clinical settings. A prospective cohort study showed that LCR had the highest prognostic value prediction among all inflammation-based scores in patients with non-metastatic colorectal cancer [26]. Iseda et al. found that a high preoperative LCR correlated

---

**Table 2** Association between inflammatory burden index and overall survival of patients with colorectal cancer

| Variables | Model a | p value | Model b | p value | Model c | p value |
|-----------|---------|---------|---------|---------|---------|---------|
|           | HR (95%CI) |        | HR (95%CI) |        | HR (95%CI) |        |
| LCR       | Continuous (per SD) | 0.824 (0.759,0.895) | < 0.001 | 0.837 (0.77,0.91) | < 0.001 | 0.848 (0.781,0.922) | < 0.001 |
|           | Cutoff value | ref | < 0.001 | ref | < 0.001 | ref |
|           | C1 (< 2813.953) | ref | ref | ref | ref |
|           | C2 (≥ 2813.953) | 0.551 (0.494,0.616) | < 0.001 | 0.589 (0.526,0.659) | < 0.001 | 0.605 (0.54,0.678) |
| Quartiles | Q1 (< 4.08) | ref | ref | ref | ref |
|           | Q2 (4.08–11.37) | 0.716 (0.622,0.825) | < 0.001 | 0.726 (0.629,0.839) | < 0.001 | 0.744 (0.644,0.86) | < 0.001 |
|           | Q3 (11.37–65.47) | 0.548 (0.473,0.635) | < 0.001 | 0.581 (0.5,0.675) | < 0.001 | 0.605 (0.52,0.704) | < 0.001 |
|           | Q4 (≥ 65.47) | 0.437 (0.376,0.508) | < 0.001 | 0.48 (0.412,0.559) | < 0.001 | 0.502 (0.43,0.585) | < 0.001 |
|           | p for trend | < 0.001 | < 0.001 | < 0.001 | < 0.001 |

Model a: No adjusted
Model b: Adjusted for age, sex, BMI, TNM stage
Model c: Adjusted for age, sex, BMI, TNM stage, tumor type, surgery, radiotherapy, chemotherapy, hypertension, diabetes, smoking, drinking, family history

*HR Hazard ratio, 95%CI 95% confidence intervals, NLR Neutrophil-to-lymphocyte ratio*
with a high serum albumin concentration, small tumor size, early Barcelona Clinic Liver Cancer stage, and low rates of microscopic vascular invasion and microscopic intrahepatic metastasis [27]. Other studies have shown that patients with hepatocellular carcinoma with low-LCR status had significantly worse outcomes of overall survival and disease-free survival than patients with high-LCR status [28]. These studies are consistent with our results, all of which indicate that LCR can be a useful biomarker to predict the prognosis of various cancers. However, our study included a larger sample size, evaluated a variety of cancer and inflammation indicators, and explored the relationship between LCR and the prognosis of patients with TNM stage IV for the first time. In addition, we confirmed for the first time that after 90 days of hospitalization, for patients with stage IV cancer, the

| Subgroup          | No.of | Interactive P Value | The Hazard Ratio   |
|-------------------|-------|---------------------|--------------------|
| All Patients      | 2424/1389 |                     | 0.85 (0.78 to 0.92) |
| Age               |       | 0.333               |                    |
| <65 yr            | 1656/917 |                     | 0.84 (0.77 to 0.93) |
| ≥65 yr            | 768/472  |                     | 0.84 (0.71 to 1.00) |
| Gender            |       | 0.34                |                    |
| Male              | 1457/877 |                     | 0.88 (0.78 to 0.98) |
| Female            | 967/512  |                     | 0.82 (0.73 to 0.94) |
| BMI               |       | 0.669               |                    |
| BMI≤18.5          | 330/209   |                     | 0.91 (0.75 to 1.09) |
| 18.5<BMI≤24       | 1416/802  |                     | 0.83 (0.73 to 0.93) |
| BMI≥24            | 665/371   |                     | 0.85 (0.74 to 0.99) |
| Hypertension      |       | 0.316               |                    |
| No                | 1884/1056 |                     | 0.86 (0.79 to 0.94) |
| Yes               | 540/333   |                     | 0.77 (0.60 to 0.98) |
| Diabetes          |       | 0.278               |                    |
| No                | 2158/1232 |                     | 0.85 (0.78 to 0.92) |
| Yes               | 266/157    |                     | 0.68 (0.37 to 1.25) |
| Family history    |       | 0.682               |                    |
| No                | 2057/1178 |                     | 0.84 (0.77 to 0.92) |
| Yes               | 367/211    |                     | 0.81 (0.66 to 1.01) |
| Surgery           |       | 0.537               |                    |
| No                | 1492/908   |                     | 0.86 (0.77 to 0.96) |
| Yes               | 932/481    |                     | 0.84 (0.74 to 0.95) |
| Radiotherapy      |       | 0.591               |                    |
| No                | 2114/1204  |                     | 0.83 (0.76 to 0.91) |
| Yes               | 310/185    |                     | 0.94 (0.76 to 1.16) |
| Chemotherapy      |       | 0.206               |                    |
| No                | 897/500    |                     | 0.78 (0.64 to 0.94) |
| Yes               | 1527/889   |                     | 0.87 (0.79 to 0.95) |

Fig. 5 The association between LCR (stratified by cut-offs 3.3125) and hazard ratios of overall survival in various subgroups. Except the stratifying variable, the model is adjusted for sex, age, BMI, tumor type, radiotherapy, chemotherapy, KPS score, albumin level, total bilirubin level, red blood cell count, platelet count, hand grip strength, reported reduced food intake, reported anorexia, and EORTC QLQ-C30 score. Notes: LCR, lymphocyte C-reactive protein ratio; BMI, body mass index; KPS, Karnofsky Performance Status Scale; QLQ-C30, EORTC Qly-C-30 questionnaire
The number of deaths in the low LCR group was significantly higher than in the high LCR group; that is, low LCR was also an unfavorable factor affecting the 90-day outcome of patients with stage IV cancer. Therefore, LCR can be used as an accurate biomarker to predict the prognosis of patients with stage IV tumors, which allows the early stratification of patients with stage IV cancer to optimize treatment.

![Fig. 6](image)

**Table 3** Association between inflammatory burden index and overall survival of patients with colorectal cancer at 90-day outcome

| Variables          | Model a | p value | Model b | p value | Model c | p value |
|--------------------|---------|---------|---------|---------|---------|---------|
|                    | HR (95%CI) |         | HR (95%CI) |         | HR (95%CI) |         |
| LCR                |          |         |          |         |          |         |
| Continuous (per SD)| 0.525 (0.335,0.823) | 0.005 | 0.54 (0.347,0.843) | 0.007 | 0.56 (0.359,0.873) | 0.011 |
| Cutoff value       |          |         |          |         |          |         |
| C1 (< 2813.953)    | ref     | < 0.001 | ref     | < 0.001 | ref     | < 0.001 |
| C2 (≥ 2813.953)    | 0.252 (0.179,0.355) | < 0.001 | 0.281 (0.198,0.397) | < 0.001 | 0.296 (0.209,0.42) | < 0.001 |
| Quartiles          | ref     | ref     | ref     |         |         |         |
| Q1 (< 4.08)        | ref     | ref     | ref     |         |         |         |
| Q2 (4.08–11.37)    | 0.344 (0.244,0.485) | < 0.001 | 0.376 (0.265,0.533) | < 0.001 | 0.390 (0.274,0.553) | < 0.001 |
| Q3 (11.37–65.47)   | 0.23 (0.156,0.34) | < 0.001 | 0.270 (0.182,0.401) | < 0.001 | 0.284 (0.191,0.423) | < 0.001 |
| Q4 (≥ 65.47)       | 0.145 (0.092,0.229) | < 0.001 | 0.170 (0.107,0.270) | < 0.001 | 0.183 (0.115,0.293) | < 0.001 |
| p for trend        |         | < 0.001 |         | < 0.001 |         | < 0.001 |

Model a: No adjusted
Model b: Adjusted for age, sex, BMI, TNM stage
Model c: Adjusted for age, sex, BMI, TNM stage, tumor type, surgery, radiotherapy, chemotherapy, hypertension, diabetes, smoking, drinking, family history

HR Hazard ratio, 95%CI 95%confidence intervals, NLR Neutrophil-to-lymphocyte ratio

Notes: LCR, lymphocyte C-reactive protein ratio; TNM, tumor, node, metastasis

**Fig. 6** The relationship between LCR and overall survival in patients with TNM stage IV. Notes: LCR, lymphocyte C-reactive protein ratio; TNM, tumor, node, metastasis
Compared to previous studies, our study was a multicenter prospective study with a large number of and explored the overall population of patients with stage IV cancer for the first time. However, this study had several limitations. First, there may have been selection bias in this study because of its retrospective design. Second, universality needs to be verified, because the selected study participants were all Chinese. Third, because LCR may change during treatment, it is still unclear whether this change can more accurately predict tumor results. In summary, this study may help doctors better evaluate the prognosis of patients with stage IV tumors and determine tumor follow-up strategies for patients with colorectal cancer.

Conclusions
In conclusion, this study demonstrated that LCR was more accurate than other inflammation-related indicators in predicting the prognosis of patients with stage IV cancer. Patients with stage IV cancer with high LCR levels exhibited a better prognosis, whereas patients with low LCR levels had worse survival times. Therefore, the LCR score can be helpful for clinicians to classify patients according to their immune, inflammatory, and nutritional status; evaluate their prognosis; and make treatment and follow-up plans accordingly. Our research results may eventually provide useful information for medical guidelines.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-10145-x.

Additional file 1.

Acknowledgements
We would like to express our sincere thanks to the INSOC project members for their substantial work on data collection and patient follow-up.

Authors’ contributions
He-Yang Zhang wrote the manuscript. Han-Ping Shi contributed to the design of the research; Hai-Lun Xie, Guo-Tian Ruan, Qi Zhang, Yi-Zhong Ge, Meng He-Yang Zhang wrote the manuscript. Han-Ping Shi contributed to the design and treatment effectiveness. This study was approved by the Institutional Review Board of each hospital (Guigang People’s Hospital, Bethune First Hospital of Jilin University, Fujian Cancer Hospital, West China Hospital of Sichuan University, Chongqing Third People’s Hospital, Foshan First People’s Hospital, Zhejiang Cancer Hospital, Yunnan Cancer Hospital, The First Affiliated Hospital of Sun Yat-sen University, Anhui Cancer Hospital, Chongqing Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital, The First Affiliated Hospital of Kunming Medical University, Chongqing Daping Hospital, Tianjin Medical University Cancer Hospital, Wuhan Tongji Hospital, Xingtai People’s Hospital (Registration number: ChiCTR1800020329).

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, 10 Tie Yi Road, Beijing 100038, China. 2 Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing 100038, China. 3 Key Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, China.

Received: 11 June 2022 Accepted: 28 September 2022

References
1. Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020. GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
2. Mcmillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–40.
3. Zhang Q, Song M, Zhang X, Ding J, Ruan G, Zhang X, et al. Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicentre cohort study. J Cachexia Sarcopenia Muscle. 2021;12(6):1466–1474.
4. Diakos C, Charles K, McMillan D, Clarke S. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–503.
5. Cruz S, Balkwill F. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12:584–96.
6. Wang N, Li Y, Zhang Y, Liao Y, Liu W. High-strength photoresponsive hydrogels enable surface-mediated gene delivery and light-induced reversible cell adhesion/detachment. Langmuir. 2014;30:11823–11832.
7. Meier M, Shi L, Wang B, Yang J, Xiao Z, Wu P, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017;58:1–13.
8. Templeton A, Ace O, McNamara M, Al-Mubarak M, Vera-Badillo F, Hermans T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Preve. 2014;23:1204–12 (a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology).
9. Kasymjanova G, MacDonald N, Agulnik J, Cohen V, Pepe C, Kreisman H, et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Current oncology (Toronto, Ont). 2010;17:52–8.
10. Pinato D, North B, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106:1439–45.

Declarations
Ethics approval and consent to participate
This study followed the Helsinki declaration. All participants signed an informed consent form and this study was approved by the Institutional Review Board of each hospital (Guigang People’s Hospital, Bethune First Hospital of Jilin University, Fujian Cancer Hospital, West China Hospital of Sichuan University, Chongqing Third People’s Hospital, Foshan First People’s Hospital, Zhejiang Cancer Hospital, Yunnan Cancer Hospital, The First Affiliated Hospital of Sun Yat-sen University, Anhui Cancer Hospital, Chongqing Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital, The First Affiliated Hospital of Kunming Medical University, Chongqing Daping Hospital, Tianjin Medical University Cancer Hospital, Wuhan Tongji Hospital, Xingtai People’s Hospital (Registration number: ChiCTR1800020329).

Consent for publication
Not applicable.
11. Proctor M, Morrison D, Talwar D, Balmer S, Fletcher C, O’Reilly D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer (Oxford, England). 2011;47:2633–41.

12. Okugawa Y, Toyama Y, Fujikawa H, Ide S, Yamamoto A, Omura Y, et al. Prognostic potential of lymphocyte-C-reactive protein ratio in patients with rectal cancer receiving preoperative chemoradiotherapy. J Gastrointest Surg. 2021;25:492–502 (official journal of the Society for Surgery of the Alimentary Tract).

13. Okugawa Y, Toyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. 2020;272:342–51.

14. Okugawa Y, Toyama Y, Yamamoto A, Shigemori T, Ichikawa T, Yin C, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clin Nutr (Edinburgh, Scotland). 2020;39:1209–17.

15. Nakamura Y, Shida D, Boku N, Yoshida T, Tanabe T, Takamizawa Y, et al. Lymphocyte-to-C-reactive protein ratio is the most sensitive inflammation-based prognostic score in patients with unresectable metastatic colorectal cancer. Dis Colon Rectum. 2021;64:1331–41.

16. Cheng C, Zhang Q, Zhuang L, Sun J. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study. Jpn J Clin Oncol. 2020;50:1141–9.

17. Lu L, Zhong C, Wei W, Li S, Mei J, Zou J, et al. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study. Liver Int. 2021;41:378–87 (official journal of the International Association for the Study of the Liver).

18. Song C, Cao J, Zhang F, Wang C, Guo Z, Lin Y, et al. Nutritional risk assessment by scored patient-generated subjective global assessment associated with demographic characteristics in 23,904 common malignant tumors patients. Nutr Cancer. 2019;71:1–11.

19. Potempa L, Rajab I, Olson M, Hart P. C-Reactive protein and cancer: interpreting the differential bioactivities of its pentameric and monomeric modified isoforms. Front Immunol. 2021;12:744129.

20. Tsilidis K, Branchini C, Guallar E, Helzlsouer K, Erlinger T, Platz E. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008;123:1133–40.

21. Gan W, Man S, Senthilselvan A, Sin D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574–80.

22. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.

23. Wang X, Mao J, Zhou T, Chen X, Tu H, Ma J, et al. Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. Theranostics. 2021;11:209–21.

24. Fearon K, Glass D, Guttridge D. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153–66.

25. Tan D, Fu Y, Tong W, Li F. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: a meta-analysis. Int J Surg (London, England). 2018;55:128–38.

26. Ou W, Zhou C, Zhu X, Lin L, Xu Q. Prognostic significance of preoperative Lymphocyte-to-C-reactive protein ratio in patients with Non-metastatic colorectal cancer. Onco Targets Ther. 2021;14:357–46.

27. Iseda N, Inoh S, Yoshizumi T, Tomyama T, Morinaga A, Shimagaki T, et al. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma. Int J Clin Oncol. 2021;26:1890–900.

28. Yugawa K, Maeda T, Kinjo N, Kawata K, Ikeda S, Edahiro K, et al. Prognostic Impact of Lymphocyte-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma. J Gastrointest Surg. 2022;26:104–12 (official journal of the Society for Surgery of the Alimentary Tract).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.